Company news

Amylyx Pharmaceuticals, Inc. news in 2024

Amylyx Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

December 3, 2024

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

November 26, 2024

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 6, 2024

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

November 3, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

October 16, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

October 14, 2024

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration

August 11, 2024

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 7, 2024

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

August 4, 2024

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

August 1, 2024

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

July 9, 2024

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

July 8, 2024

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 3, 2024

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

May 8, 2024

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

May 7, 2024

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

May 1, 2024

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

April 9, 2024

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

April 7, 2024

Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy

April 3, 2024

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors

March 13, 2024

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

March 7, 2024

Amylyx Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

February 22, 2024

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

February 21, 2024

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

February 14, 2024

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

February 14, 2024

Amylyx Pharmaceuticals Announces Completion of Enrollment in HELIOS, a Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome

February 7, 2024

Calls in 2024

Decks in 2024